Skip to main content
Skip to footer
Home
About us
Our Business
Strategy and business model
Business Development
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Ovarian cancer
Chronic Lymphocytic Leukemia (CLL)
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Home
About us
Our Business
Strategy and business model
Business Development
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Ovarian cancer
Chronic Lymphocytic Leukemia (CLL)
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Start
>
News
>
Regulatory
>
Listing Regulation
Listing Regulation
Interim Report for Kancera AB (publ) Q1 2013
Full Year Report 2012 for Kancera AB (publ) January 1 – December 31, 2012
Interim Report for Kancera AB (publ) Q3 2012
Interim Report for Kancera AB (publ) Q2 2012
Interim Report for Kancera AB (publ) Q1 2012
Full Year Report 2011 for Kancera AB (publ)
Interim Report for Kancera AB (publ)
Notice of Extraordinary General Meeting Kancera AB
Interim Report for Kancera AB (publ)
Kancera Implements Rights Issue to Develop the Company´s ROR Technology